Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

AstraZeneca PLC AZN shares inched down 0.09% to £111.70 Tuesday, on what proved to be an all-around favorable trading session ...

U.S. markets stabilized Tuesday following a wipeout a day earlier when a Chinese AI startup startled markets with its ...